Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | E554_K558del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT E554_K558del results in the deletion of five amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 554 to 558 (PMID: 16226710). E554_K558del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT E554_K558del KIT mutant KIT exon11 KIT exon 11 del KIT E554_K558del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727429_54727443del15 |
cDNA | c.1661_1675del15 |
Protein | p.E554_K558del |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000222 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727429_54727443del15 | c.1661_1675del15 | p.E554_K558del | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT E554_K558del | gastrointestinal stromal tumor | predicted - sensitive | Binimetinib + Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) and Mektovi (binimetinib) combination treatment had manageable toxicity and resulted in a 99% pathological response and 29% RECIST response in a patient with a rectal gastrointestinal stromal tumor harboring KIT E554_K558del (PMID: 35041493; NCT01991379). | 35041493 |